Abgenix Announces Data Presentations for Panitumumab at AACR and ASCO Annual Meetings
Friday April 15, 6:30 am ET
FREMONT, Calif., April 15 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX - News) today announced upcoming presentations of clinical and preclinical data from studies of panitumumab, a fully human monoclonal antibody currently in pivotal clinical trials as a third line monotherapy in colorectal cancer, will be presented at the American Association for Cancer Research (AACR) annual meeting April 16-20 in Anaheim, California and the 41st American Society of Clinical Oncology (ASCO) annual meeting May 13-17 in Orlando, Florida.
AACR
The following abstracts are being presented at the AACR meeting:
-- "Gene Expression Profiles Can Predict Panitumumab Monotherapy
Responsiveness in Xenograft Models -- A 'Balanced' Approach" will be
presented in the Cellular and Molecular Biology 1, Expression Profiling
and Analysis of Cancer Biology session on Sunday, April 17 from
8:00 a.m. to 12:00 p.m. (Abstract #1);
-- "Activity of Panitumumab Against Mutant and Wild Type EGFr NSCLC Cell
Lines and Xenografts" will be presented in the Molecular Biology 56
session on Tuesday, April 19 from 1:00 PM to 5:00 PM (Abstract #4494);
and
-- "Identification and Preclinical Characterization of EGFr Somatic Gene
Mutations from a Panitumumab Phase 2 NSCLC Clinical Trial: Discovery of
a Novel Mutation with Panitumumab Sensitivity and Gefitinib Resistance"
will be presented in the Late-Breaking Poster session Tuesday, April 19
from 1:00 p.m. to 5:00 p.m. (Abstract #LB205).
ASCO
The following abstracts will be presented at ASCO in May:
-- "Updated Results from a Dose and Schedule Study of Panitumumab
(ABX-EGF) Monotherapy, in Patients with Advanced Solid Malignancies"
will be presented on Sunday, May 15 from 8:00 a.m. to 12:00 p.m. during
the General Poster Session; and
-- "Safety and Efficacy of Panitumumab Monotherapy in Patients with
Metastatic Colorectal Cancer (mCRC)" will be presented during a Poster
Discussion on Tuesday May 17 from 8:00 a.m. to 12:00 p.m.
About Panitumumab
Co-developed by Amgen and Abgenix, panitumumab is an investigational product in a novel class of targeted cancer treatments called epidermal growth factor receptor (EGFr) inhibitors. Panitumumab (formerly ABX-EGF) is the first fully human monoclonal antibody directed against EGFr and is being evaluated as both a monotherapy and in combination with other agents for the treatment of various types of cancer, including colorectal, lung and kidney. Panitumumab is generated with Abgenix's XenoMouse® technology, which creates a fully human monoclonal antibody that contains no murine (mouse) protein. The fully human nature of panitumumab may result in a favorable safety profile with a low incidence of infusion reactions, antigenicity and allergic response. Theseare attributes currently being investigated in clinical trials. Pivotal clinical studies evaluating panitumumab as a third-line monotherapy in colorectal cancer patients are ongoing with a convenient every-other-week dosing regimen.... |
